We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29).
- Authors
Kim, Kyung; Kim, Jae; Ji, Eun; Jang, Jun; Kim, Jin; Kwon, Ji-Hyun; Kim, Inho; Park, Seonyang; Velikova, Galina; Yoon, Sung-Soo; Oh, Jung; Kim, Kyung Im; Kim, Jae Hyun; Ji, Eun Hee; Jang, Jun Ho; Kim, Jin Seok; Oh, Jung Mi
- Abstract
<bold>Purpose: </bold>We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals.<bold>Methods: </bold>A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed.<bold>Results: </bold>Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach's α, except for the scales body image and the inpatient issues. Cronbach's α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT.<bold>Conclusions: </bold>The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
- Subjects
SOUTH Korea; CANCER treatment; CANCER chemotherapy; DRUG dosage; QUESTIONNAIRES; PSYCHOMETRICS; CANCER patients; STEM cell transplantation; QUALITY of life; PHYSIOLOGY; MENTAL health; ANTINEOPLASTIC agents; COMPARATIVE studies; DOSE-effect relationship in pharmacology; HEMATOPOIETIC stem cell transplantation; LONGITUDINAL method; RESEARCH methodology; MEDICAL cooperation; RESEARCH; RESEARCH evaluation; RESEARCH funding; SICKNESS Impact Profile; TUMORS; EVALUATION research; SPECIALTY hospitals
- Publication
Quality of Life Research, 2016, Vol 25, Issue 4, p881
- ISSN
0962-9343
- Publication type
journal article
- DOI
10.1007/s11136-015-1121-5